The 51 references in paper V. Dobronravov A., E. Bogdanova O., В. Добронравов А., Е. Богданова О. (2014) “Патогенез нарушений обмена фосфатов при хронической болезни почек: все ли так ясно, как кажется? // Pathogenesis of phosphate exchange disorders in CKD: is all as clear as seems to be?” / spz:neicon:nefr:y:2014:i:2:p:42-46

1
Kestenbaum В, Sampson JN, Rudser KD. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16(2):520-528
(check this in PDF content)
2
Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71(1):31-38
(check this in PDF content)
3
Fang Y, Ginsberg C, Sugatani T et al. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 2014;85(1):142-150
(check this in PDF content)
4
Portale AA, Halloran BP, Murphy MM et al. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986;77(1):7-12
(check this in PDF content)
5
Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int 2011;79:3-8
(check this in PDF content)
6
Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996;28(4):596-602
(check this in PDF content)
7
Martin DR, Ritter CS, Slatopolsky E et al. Acute regulation of parathyroid hormone by dietary phosphate. Am J Physiol Endocrinol Metab 2005;289(4):729-734
(check this in PDF content)
8
Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant 2002 Aug;17(8):1419-1425
(check this in PDF content)
9
Murayama A, Takeyama K, Kitanaka S et al. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology. 1999;140(5):2224-2231
(check this in PDF content)
10
Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010;78:975–980
(check this in PDF content)
11
Prié D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/ Klotho system. Clin J Am Soc Nephrol 2010;5(9):1717-1722
(check this in PDF content)
12
Andrukhova O, Zeitz U, Goetz R et al. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 2012;51(3):621-628
(check this in PDF content)
13
Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho. Нефрология 2011; 15(4): 11-20
(check this in PDF content)
14
Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol 2013;180:47-63
(check this in PDF content)
15
Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444(7120):770-774
(check this in PDF content)
16
Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012;92(1):131155
(check this in PDF content)
17
Kuro-o М. Phosphate and Klotho. Kidney International 2011;79 (Suppl 121):20–23
(check this in PDF content)
18
Cha SK, Ortega B, Kurosu H et al. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A 2008;105(28):98059810
(check this in PDF content)
19
Drüeke T. Klotho, FGF23, and FGF receptors in chronic kidney disease: a yin-yang situation? Kidney Int 2010;78(11):10571060
(check this in PDF content)
20
Imura A, Tsuji Y, Murata M et al. alpha-Klotho as a regulator of calcium homeostasis. Science 2007;316(5831):1615-1618
(check this in PDF content)
21
Hu MC, Shi M, Zhang J et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010;24(9):3438-3450
(check this in PDF content)
22
Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79(12):1370-1378
(check this in PDF content)
23
Pavik I, Jaeger P, Ebner L. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013;28(2):352359
(check this in PDF content)
24
Aizawa H, Saito Y, Nakamura T et al. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 1998;249:865–871
(check this in PDF content)
25
Haruna Y, Kashihara N, Satoh M et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA 2007; 104: 2331–2336
(check this in PDF content)
26
Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009; 54:810–817
(check this in PDF content)
27
Asai O, Nakatani K, Tanaka T et al. Decreased renal alphaKlotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int 2012;81:539–547
(check this in PDF content)
28
Fliser D, Kollerits B, Never U et al. Fibroblast growth factor 23 (FGF-23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18 (9): 2600–2608
(check this in PDF content)
29
Titan SM, Zatz R, Graciolli FG et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2010; 6 (2): 241–247
(check this in PDF content)
30
Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359 (6): 584–592
(check this in PDF content)
31
Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22 (1): 124–136
(check this in PDF content)
32
Vervloet M, Larsson T. Fibroblast growth factor-23 and Klotho in chronic kidney disease. Kidney Int 2011; Suppl. 1: 130135
(check this in PDF content)
33
Mirza MA, Larsson A, Lind L et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205 (2): 385–390
(check this in PDF content)
34
Mirza MA, Hansen T, Johansson L et al. Relationship between circulating FGF-23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009; 24 (10): 3125–3131
(check this in PDF content)
35
Yilmaz MI, Sonmez A, Saglam M et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78 (7): 679–685
(check this in PDF content)
36
Kirkpantur A, Balci M, Gurbuz CA et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011; 26 (4): 1346–1354
(check this in PDF content)
37
Kusaba T, Okigawa M, Matui A et al. Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci USA 2010; 107 (45): 19308–19313
(check this in PDF content)
38
Nagai R, Saito Y, Ohyama Y et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 2000; 57 (5): 738–746
(check this in PDF content)
39
Sakan H, Nakatani K, Asai O et al. Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism. PLoS One 2014;9(1):e86301
(check this in PDF content)
40
Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205–2215
(check this in PDF content)
41
Prié D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/ Klotho system. Clin J Am Soc Nephrol 2010;5(9):1717-1722
(check this in PDF content)
42
Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82(7):737-747
(check this in PDF content)
43
Isakova T, Gutierrez O, Shah A. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008;19(3):615-623
(check this in PDF content)
44
Haussler MR, Whitfield GK, Kaneko I et al. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 2012;13(1):57-69.
(check this in PDF content)
45
Kido S, Kaneko I, Tatsumi S et al.Vitamin D and type II sodium-dependent phosphate cotransporters. Contrib Nephrol 2013;180:86-97
(check this in PDF content)
46
Biber J, Hernando N, Forster I. Phosphate transporters and their function. Annu Rev Physiol 2013;75:535-550
(check this in PDF content)
47
Sitara D. Correlation among hyperphosphatemia, type II sodium phosphate transporter activity, and vitamin D metabolism in Fgf-23 null mice. Ann N Y Acad Sci 2007;1116:485-493
(check this in PDF content)
48
Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 2012;22(1):61-86
(check this in PDF content)
49
Quarles LD. «FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.» Am J Physiol Endocrinol Metab 2003;285(1):1–9
(check this in PDF content)
50
Villa-Bellosta R, Ravera S, Sorribas V et al. The Na+Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi. Am J Physiol Renal Physiol 2009;296:691–699
(check this in PDF content)
51
Добронравов ВА, Богданова ЕО, Семенова НЮ, и др. Почечная экспрессия белка αKlotho, фактор роста фибробластов 23 и паратиреоидный гормон при экспериментальном моделировании ранних стадий хронического повреждения почек. Нефрология 2014; 18(2): 42-45
(check this in PDF content)